|Articles|March 7, 2011
Marken Announces the Opening of a Directly Owned Clinical Trial Supply Depot in Singapore.
Advertisement
As part of Marken’s continued expansion of services in the APAC region, they have relocated and expanded their Singapore office to further support clients’ needs for specialty logistics services. This expansion incorporates a new directly owned, purpose-built Singapore depot to support growing customer demand for Investigational Medical Product distribution.
The new GMP compliant facility enables clients to leverage Marken’s global expertise in Life Science logistics while adding key Life Science specialty services for their programs in the Asia Pacific and Middle East regions. In recent presentation to Marken employees, Gerard Barba, CEO of Marken announced “ The opening of our directly owned depot in Singapore sets the corner stone of an expanding global network of GMP compliant distribution centers for Marken. “
The new 14,500 sq. ft. Clinical Trial Supply Depot offers the full range of secured storage conditions including
- Secured Controlled Drug (ambient)
- 15 – 25C (controlled ambient)
- -2- 8C (cold storage)
- -20C (frozen)
- -80C (deep frozen)
Clinical Trial Logistics services offered:
- Storage and distribution
- Drug returns and destruction
- Kit building
- Biological specimen storage in ultra low freezers – short and long term
The expanded Marken office in Singapore provides Life Science material logistics and Clinical Trial Supply management for Pharmaceutical and Biotech customers throughout the Asia Pacific region. This represents Marken's latest investment in the region, which in 2010 saw the opening of a new office in Tokyo.s
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
- Q&A: Strategies for Successful Global Clinical Trial Delivery
September 12th 2025
- Vabysmo Shows Long-Term Efficacy and Safety in Wet AMD, PCV Patients
September 12th 2025
- Latest NIMBLE Study Results Highlight Progress in gMG Research
September 12th 2025
- ACT Brief Episode 8: Expert Insights on the Future of Obesity Drug Trials
September 11th 2025
Advertisement
Advertisement